• The next frontier is combination therapy with NUCs (usually), with
Interferon (maybe to rarely) - but most importantly combining new
classes
• Our bias is that RNAi will be at the center of many/most/?all combos
due the ability to affect the entire HBV transcriptome, including
integrated DNA-sourced RNA
• The bar will be very high for activity (functional cure) and
safety/tolerability
• Immuno-oncology agents (PD1/PDL1) monoclonals may play a role
but safety concerns may dominate. In the meantime, other immune
stimulation approaches are being tried
发表于 2018-9-7 14:01
